Nisa Investment Advisors LLC Sells 354,629 Shares of Pfizer Inc. (NYSE:PFE)

Nisa Investment Advisors LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 20.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,370,292 shares of the biopharmaceutical company’s stock after selling 354,629 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Pfizer were worth $34,723,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Providence Capital Advisors LLC raised its position in shares of Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $3,034,000 after buying an additional 409 shares in the last quarter. Donaldson Capital Management LLC raised its position in shares of Pfizer by 1.2% during the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock valued at $947,000 after buying an additional 410 shares in the last quarter. William B. Walkup & Associates Inc. raised its position in shares of Pfizer by 1.2% during the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock valued at $1,044,000 after buying an additional 454 shares in the last quarter. Sutton Place Investors LLC raised its position in shares of Pfizer by 5.6% during the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 472 shares in the last quarter. Finally, Balboa Wealth Partners raised its position in shares of Pfizer by 1.6% during the 4th quarter. Balboa Wealth Partners now owns 30,678 shares of the biopharmaceutical company’s stock valued at $814,000 after buying an additional 480 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.02 during midday trading on Wednesday, reaching $25.61. The company had a trading volume of 3,543,906 shares, compared to its average volume of 41,652,004. The business’s 50-day simple moving average is $23.80 and its 200 day simple moving average is $24.81. The stock has a market cap of $145.57 billion, a P/E ratio of 18.56, a P/E/G ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business’s quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the company posted $0.82 earnings per share. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.72%. Pfizer’s dividend payout ratio is currently 124.64%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PFE. HSBC reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Morgan Stanley raised their target price on shares of Pfizer from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 30th. Wolfe Research raised their target price on shares of Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a research report on Wednesday, April 30th. Finally, Leerink Partners reduced their target price on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.